Clinical Trial

Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-17.
Trial Details
NCT Number NCT07487402
Lead Sponsor Zhejiang University
Collaborators: Leman Biotech Co., Ltd.
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 27 participants
Start Date 2026-03-30
Primary Completion 2028-12-15 (estimated)
Study Completion 2029-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-21